AbbVie Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
AbbVie wird ein jährliches Gewinn- und Umsatzwachstum von 26.7% bzw. 6.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 27.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 228.1% betragen.
Wichtige Informationen
26.7%
Wachstumsrate der Gewinne
27.43%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 25.1% |
| Wachstumsrate der Einnahmen | 6.3% |
| Zukünftige Eigenkapitalrendite | 228.15% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 29 Jun 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Narrativ-Update • Jun 23
ABBV: Future Returns Will Hinge On Apogee Deal And Immunology Pipeline
Analysts have made only a modest adjustment to AbbVie’s fair value narrative, reflecting a slightly higher discount rate and updated views on margins and long term P/E in light of the proposed $10.9 billion Apogee Therapeutics deal and its implications for competition and atopic dermatitis market potential. Analyst Commentary Recent research on AbbVie around the proposed US$10.9b Apogee Therapeutics acquisition highlights a mix of optimism about growth opportunities in immunology and atopic dermatitis, alongside caution about execution risk, competition, and valuation.Seeking Alpha • Jun 19
AbbVie: Immunology Cash Flow Funds Oncology Expansion
Summary I continue to cover AbbVie with a 'Buy' rating due to its R&D achievements. So, in the past 3 months, Decnupaz and Skinvive by Juvederm have received FDA approvals. Moreover, a week ago, AbbVie reported promising results from the Phase 3 CLL14 trial for the treatment of chronic lymphocytic leukemia patients. Meanwhile, Venclexta generated $770 million in revenue for AbbVie in Q1, up 15.8% year-over-year and 8.5% QoQ. Also, inthis article, you will know why the superiority of UCB's Bimzelx over Skyriziin the Phase 3 BE BOLD study doesn't threaten the sales growth of AbbVie's IL-23 inhibitor. Read the full article on Seeking AlphaAnalyseartikel • Jun 16
AbbVie (ABBV) Stock Could Be 12.6% Undervalued After CLL14 Trial Update
AbbVie (ABBV) is back in focus after releasing nine year final results from its Phase 3 CLL14 trial, where a fixed duration venetoclax plus obinutuzumab regimen improved progression free survival in untreated CLL patients. See our latest analysis for AbbVie. The latest CLL14 update lands after a mixed few sessions for AbbVie, with the share price slipping 2.7% on the day to $221.59, while still showing a 5.3% 30 day share price return and a 19.9% one year total shareholder return that points...Narrativ-Update • Jun 06
ABBV: Future Returns Will Depend On Expanding Immunology And IBD Pipeline Execution
AbbVie’s updated analyst price target edges higher to $253.55 from $249.43 as analysts factor in slightly higher profit margin assumptions, modestly lower revenue growth expectations, a reduced discount rate, and a somewhat lower future P/E multiple, with recent research highlighting the depth of the inflammatory bowel disease pipeline and broader R&D optionality. Analyst Commentary Recent Street research on AbbVie shows a mix of optimism and caution, with multiple price target revisions clustered within a relatively tight range and commentary that keeps attention on the inflammatory bowel disease pipeline and broader R&D portfolio.Analyseartikel • May 15
We Think You Can Look Beyond AbbVie's (NYSE:ABBV) Lackluster Earnings
The market was pleased with the recent earnings report from AbbVie Inc. ( NYSE:ABBV ), despite the profit numbers being...Narrativ-Update • Apr 23
ABBV: Future Returns Will Rely On Immunology Expansion And Operating Leverage Execution
Analysts made a small upward adjustment to AbbVie’s fair value estimate to about $249. The modest change reflects a mix of slightly higher assumed discount rates and future P/E multiples, alongside recent shifts in Street price targets, including both raises and trims from firms such as Piper Sandler, Guggenheim, Cantor Fitzgerald, Evercore ISI, Citi and UBS, as well as fresh bullish initiations from Canaccord, RBC Capital and Barclays.Narrativ-Update • Apr 08
ABBV: Future Returns Will Hinge On Immunology Encore And Operating Leverage Execution
Analysts have made a modest upward adjustment to AbbVie’s price target, reflecting updated views on its immunology pipeline potential, operating leverage, and the ongoing debate about whether recent share underperformance and selloffs adequately reflect competitive risks. Analyst Commentary Recent research on AbbVie highlights a split view, with some analysts focusing on the upside from the immunology pipeline and operating leverage, while others point to valuation and competitive questions after a period of share underperformance.Narrativ-Update • Mar 24
ABBV: Future Returns Will Hinge On Immunology Encore Outweighing Competitive Concerns
Narrative Update The analyst price target for AbbVie has been adjusted slightly higher to reflect a fair value move to about $249. Analysts point to early stage indication expansion, operating leverage potential, and ongoing immunology pipeline developments, even as some firms flag emerging competition and a more balanced risk and reward profile.Narrativ-Update • Mar 10
ABBV: Future Returns Will Depend On Immunology Encore And Deal Optionality Uncertainty
The analyst price target for AbbVie edges higher to align with our fair value shift from $248.29 to $248.86, as analysts highlight ongoing indication expansion in immunology, potential operating leverage, and multiple expansion drivers, even as some firms note emerging competition and a more balanced risk and reward profile. Analyst Commentary Recent research on AbbVie reflects a split view, with some analysts pointing to upside tied to immunology growth and pipeline execution, while others flag competition risk and a more balanced risk and reward profile at current levels.Narrativ-Update • Feb 22
ABBV: Future Returns Will Rely On Immunology Encore And Evolving Deal Optionality
Our updated AbbVie narrative reflects a modest price target increase to about $248 per share, as analysts point to potential operating leverage, room for P/E multiple expansion, and a pipeline of proof-of-concept and immunology programs that could support slightly higher revenue growth assumptions, even as margin expectations are trimmed. Analyst Commentary Recent research shows a mix of optimism and caution around AbbVie, with several firms adjusting price targets and ratings as they reassess execution risks, competitive pressures, and the potential impact of the pipeline on valuation.Narrativ-Update • Feb 07
ABBV: Future Returns Will Depend On Immunology Pipeline Clarity And M&A Uncertainty
Analysts have trimmed their price targets for AbbVie by a small amount. This reflects slightly lower revenue growth and P/E assumptions, while also incorporating a modestly higher profit margin and recent mixed research views around competition and pipeline visibility.Narrativ-Update • Jan 24
ABBV: Future Returns Will Hinge On Post-Humira Immunology And Deal Optionality
Analysts have nudged their price target for AbbVie slightly higher to reflect a fair value estimate of about $245 per share, supported by updated assumptions for revenue growth, profit margins, and a modestly lower future P/E. Recent research highlights both increased price targets and more cautious views around competition and the sustainability of outperformance in key immunology drugs.Narrativ-Update • Jan 09
ABBV: Future Returns Will Depend On Post-Humira Immunology And Pipeline Execution
Analysts have trimmed their AbbVie fair value estimate by about $0.10 per share to roughly $244.56. This reflects a mix of slightly higher risk assumptions, modestly adjusted revenue and margin expectations, and a more balanced set of views after recent downgrades and price target changes that suggest outperformance is already well reflected in the current share price.Analyseartikel • Jan 08
AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73
AbbVie Inc. ( NYSE:ABBV ) will increase its dividend from last year's comparable payment on the 17th of February to...Narrativ-Update • Dec 21
ABBV: Future Returns Will Hinge On Post-Humira Immunology And Pipeline Execution
Analysts have nudged our AbbVie fair value estimate slightly higher, from $243.55 to $244.68. This reflects modestly stronger long term revenue growth expectations for key immunology franchises and pipeline assets, partially offset by slightly lower margin assumptions and a broadly constructive but mixed backdrop of recent price target revisions and rating changes across the Street.Narrativ-Update • Dec 07
ABBV: Future Performance Will Depend On Extended Exclusivity And Pipeline Execution
Analysts have nudged their average price target on AbbVie modestly higher to reflect a wave of target increases into the mid 240s to low 260s dollar range, supported by stronger visibility into Skyrizi and Rinvoq driven growth, extended Rinvoq exclusivity, and a more favorable large cap biopharma backdrop despite mixed ratings changes. Analyst Commentary Recent research paints a generally constructive picture on AbbVie, with most price target revisions skewing higher even as some firms move to the sidelines.Analyseartikel • Dec 02
AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73
The board of AbbVie Inc. ( NYSE:ABBV ) has announced that it will be paying its dividend of $1.73 on the 17th of...Narrativ-Update • Nov 23
ABBV: Future Performance Will Depend On Pipeline Expansion And Patent Protections
AbbVie’s analyst price target has increased modestly from $241.29 to $243.55. Analysts cite resilient performance in immunology products, extended Rinvoq exclusivity, and improving fundamentals as key drivers of sentiment.Analyseartikel • Nov 18
AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73
The board of AbbVie Inc. ( NYSE:ABBV ) has announced that it will be paying its dividend of $1.73 on the 17th of...Narrativ-Update • Nov 08
ABBV: Future Performance Will Reflect Balance Between Patent Wins and Product Pressures
AbbVie's analyst price target has risen modestly from $237.48 to $241.29. Analysts cite resilient fundamentals and long-term patent settlements, which help offset recent industry downgrades and softer performance in some business units.Narrativ-Update • Oct 25
Continued Expansion in Neuroscience and Immunology Will Drive Leadership Beyond 2025
AbbVie's analyst price target has been raised from approximately $233 to $237 per share. Analysts cite ongoing revenue growth, improved margins, and extended exclusivity for key products as the main drivers behind the upward revision.Narrativ-Update • Oct 11
Expanding Immunology And Neuroscience Will Reshape Global Healthcare
AbbVie's analyst price target has increased significantly, rising from $227 to $233 per share. Analysts cite recent positive developments in patent settlements and stronger-than-expected performance across key growth drivers as the main rationales.Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 78,092 | 21,855 | 34,425 | 33,187 | 19 |
| 12/31/2027 | 72,732 | 19,023 | 33,347 | 30,282 | 24 |
| 12/31/2026 | 67,238 | 14,561 | 29,402 | 25,447 | 24 |
| 3/31/2026 | 62,819 | 3,595 | 19,980 | 21,224 | N/A |
| 12/31/2025 | 61,160 | 4,186 | 17,816 | 19,030 | N/A |
| 9/30/2025 | 59,644 | 2,348 | 19,684 | 20,860 | N/A |
| 6/30/2025 | 58,328 | 3,723 | 18,239 | 19,283 | N/A |
| 3/31/2025 | 57,367 | 4,155 | 15,385 | 16,401 | N/A |
| 12/31/2024 | 56,334 | 4,238 | 17,832 | 18,806 | N/A |
| 9/30/2024 | 55,533 | 5,081 | 15,623 | 16,511 | N/A |
| 6/30/2024 | 55,000 | 5,298 | 17,780 | 18,638 | N/A |
| 3/31/2024 | 54,403 | 5,951 | 21,891 | 22,686 | N/A |
| 12/31/2023 | 54,318 | 4,820 | 22,062 | 22,839 | N/A |
| 9/30/2023 | 55,138 | 6,471 | 24,729 | 25,514 | N/A |
| 6/30/2023 | 56,023 | 8,635 | 24,799 | 25,542 | N/A |
| 3/31/2023 | 56,741 | 7,535 | 23,520 | 24,228 | N/A |
| 12/31/2022 | 58,054 | 11,782 | 24,248 | 24,943 | N/A |
| 9/30/2022 | 57,819 | 13,343 | 21,921 | 22,590 | N/A |
| 6/30/2022 | 57,349 | 12,569 | 22,214 | 22,923 | N/A |
| 3/31/2022 | 56,725 | 12,407 | 22,047 | 22,808 | N/A |
| 12/31/2021 | 56,197 | 11,468 | 21,990 | 22,777 | N/A |
| 9/30/2021 | 55,169 | 7,465 | 21,677 | 22,556 | N/A |
| 6/30/2021 | 53,729 | 6,599 | 19,572 | 20,451 | N/A |
| 3/31/2021 | 50,195 | 5,092 | 17,789 | 18,650 | N/A |
| 12/31/2020 | 45,804 | 4,556 | 16,790 | 17,588 | N/A |
| 9/30/2020 | 40,650 | 7,324 | 15,327 | 16,009 | N/A |
| 6/30/2020 | 36,227 | 6,906 | 14,115 | 14,734 | N/A |
| 3/31/2020 | 34,057 | 8,395 | 13,552 | 14,122 | N/A |
| 12/31/2019 | 33,266 | 7,842 | N/A | 13,324 | N/A |
| 9/30/2019 | 32,867 | 3,232 | N/A | 13,441 | N/A |
| 6/30/2019 | 32,624 | 4,093 | N/A | 13,410 | N/A |
| 3/31/2019 | 32,647 | 5,333 | N/A | 13,799 | N/A |
| 12/31/2018 | 32,753 | 5,657 | N/A | 13,427 | N/A |
| 9/30/2018 | 32,187 | 7,531 | N/A | 12,619 | N/A |
| 6/30/2018 | 30,946 | 6,419 | N/A | 11,366 | N/A |
| 3/31/2018 | 29,612 | 6,352 | N/A | 10,503 | N/A |
| 12/31/2017 | 28,216 | 5,283 | N/A | 9,960 | N/A |
| 9/30/2017 | 27,273 | 6,615 | N/A | 8,917 | N/A |
| 6/30/2017 | 26,710 | 6,582 | N/A | 7,100 | N/A |
| 3/31/2017 | 26,218 | 6,278 | N/A | 7,015 | N/A |
| 12/31/2016 | 25,638 | 5,923 | N/A | 7,041 | N/A |
| 9/30/2016 | 25,242 | 6,048 | N/A | 7,463 | N/A |
| 6/30/2016 | 24,754 | 5,690 | N/A | 8,164 | N/A |
| 3/31/2016 | 23,777 | 5,448 | N/A | 8,078 | N/A |
| 12/31/2015 | 22,859 | 5,118 | N/A | 7,535 | N/A |
| 9/30/2015 | 21,911 | 2,790 | N/A | 4,994 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: ABBVDas prognostizierte Gewinnwachstum (26.7% pro Jahr) liegt über der Sparquote (3.5%).
Ertrag vs. Markt: ABBVDie Erträge des Unternehmens (26.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (18.4% pro Jahr).
Hohe Wachstumserträge: ABBVEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: ABBVDie Einnahmen des Unternehmens (6.3% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (12.7% pro Jahr).
Hohe Wachstumseinnahmen: ABBVDie Einnahmen des Unternehmens (6.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: ABBVDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich sehr hoch sein (228.1%).
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/05 03:01 |
| Aktienkurs zum Tagesende | 2026/07/02 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
AbbVie Inc. wird von 51 Analysten beobachtet. 24 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Luisa Hector | Berenberg |